The antihyperglycemic and hypolipidemic activities of a sulfur-oxidovanadium(IV) complex

Lidiane M A Lima; Amanda K J P F da Silva; Eucilene K Batista; Kahoana Postal; Kateryna Kostenkova; Alex Fenton; Debbie C Crans; Wagner E Silva; Mônica F Belian; Eduardo C Lira

doi:10.1016/j.jinorgbio.2023.112127

The antihyperglycemic and hypolipidemic activities of a sulfur-oxidovanadium(IV) complex

J Inorg Biochem. 2023 Apr:241:112127. doi: 10.1016/j.jinorgbio.2023.112127. Epub 2023 Jan 27.

Affiliations

¹ Departamento de Química, Universidade Federal Rural de Pernambuco, 52171-900 Recife, PE, Brazil.
² Departamento de Fisiologia e Farmacologia, Centro de Biociências, Universidade Federal de Pernambuco, 50670-901 Recife, PE, Brazil.
³ Departamento de Química, Universidade Federal do Paraná, 81531-980 Curitiba, PR, Brazil; Department of Chemistry, Colorado State University, Fort Collins, CO 80513, USA.
⁴ Department of Chemistry, Colorado State University, Fort Collins, CO 80513, USA.
⁵ Department of Chemistry, Colorado State University, Fort Collins, CO 80513, USA; Cell and Molecular Biology Program, Colorado State University, Fort Collins, CO 80513, USA.
⁶ Departamento de Química, Universidade Federal Rural de Pernambuco, 52171-900 Recife, PE, Brazil. Electronic address: mfbelian@gmail.com.

PMID: 36822888
DOI: 10.1016/j.jinorgbio.2023.112127

Abstract

This study describes the synthesis, characterization, and biological activity of a new class of antidiabetic oxidovanadium(IV)-complexes with S₂O₂ coordination mode. The target complex 3,6-dithio-1,8-octanediolatooxidovanadium(IV), abbreviated as ([V^IVO(octd)]), where octd = 3,6-dithio-1,8-octanediol, is formed from the reaction between the 3,6-dithio-1,8-octanediol and vanadyl sulfate (V^IVOSO₄). The effects of treatment with ([V^IVO(octd)] on blood glucose, lipidic profile, body weight, food intake, water intake, urinary volume, glycogen levels, and biomarkers for liver toxicity were investigated using a streptozotocin (STZ)-induced diabetic Wistar rats model. The results have shown that the [V^IVO(octd)] complex caused a significant decrease in blood glucose (247.6 ± 19.3 mg/dL vs 430.1 ± 37.6 mg/dL diabetic group, p < 0.05), triglycerides (TG, 50%) and very low-density cholesterol (VLDL-C, 50%) levels in STZ-diabetic rats after 3 weeks of treatment. The [V^IVO(octd)] has shown antihyperglycemic activity in diabetic rats as well as a reduction in elevated lipid levels. Time-dependent studies using EPR and ⁵¹V NMR spectroscopy of [V^IVO(octd)] were done in aqueous solutions to determine the complex stability and species present in the oral gavage solution used for complex administration. The spectroscopic studies have shown that the antidiabetic/hypolipidemic activity could be attributed to [V^IVO(octd)], vanadium species resulting from redox processes, the hydrolysis of [V^IVO(octd)] and its decomposition products, or some combination of these factors. In summary, the oxidovanadium(IV) complex containing the S₂O₂ donor ligand has desirable antidiabetic properties eliminating the symptoms of Diabetes mellitus and its comorbidities.

Keywords: Antidiabetic; Diabetes mellitus; Hypolipidemic; Insulin-like; Oxidovanadium(IV) complex; S(2)O(2) coordination mode.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Animals
Blood Glucose
Diabetes Mellitus, Experimental*
Hypoglycemic Agents* / pharmacology
Rats
Rats, Wistar
Vanadium / chemistry

Substances

Hypoglycemic Agents
Blood Glucose
5,7,11,13-octadecatrayne-1,18-diol
Vanadium